Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating that they no longer beneficially own more than five percent of bluebird bio, Inc.'s common stock. The filing, dated September 30, 2024, shows that each reporting person now owns 0% of the company's common stock, effectively ceasing their status as major shareholders. The addresses for all reporting persons are listed as 77 West Wacker Drive, 7th Floor, Chicago, IL 60601. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Alyeska Investment Group and Alyeska Fund GP, LLC classified as investment advisers and parent holding companies or control persons. The certification signed by Jason Bragg, Chief Financial Officer for both Alyeska entities, and Anand Parekh individually, asserts that the shares were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of bluebird bio, Inc.

Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have filed an amended Schedule 13G/A with the United States Securities and Exchange Commission, indicating that they no longer beneficially own more than five percent of bluebird bio, Inc.'s common stock. The filing, dated September 30, 2024, shows that each reporting person now owns 0% of the company's common stock, effectively ceasing their status as major shareholders. The addresses for all reporting persons are listed as 77 West Wacker Drive, 7th Floor, Chicago, IL 60601. The filing was made in accordance with Rule 13d-1(b) of the Securities Exchange Act of 1934, with Alyeska Investment Group and Alyeska Fund GP, LLC classified as investment advisers and parent holding companies or control persons. The certification signed by Jason Bragg, Chief Financial Officer for both Alyeska entities, and Anand Parekh individually, asserts that the shares were acquired and held in the ordinary course of business and not for the purpose of changing or influencing the control of bluebird bio, Inc.